Home>
US Stocks>
Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc share price today

(SUPN)

Supernus Pharmaceuticals Inc share price is $36.97 & ₹3,132.47 as on 6 Dec 2024, 2.30 'hrs' IST

$36.97

▲

-0.18

(-0.48%)

Market is closed - opens 8 PM, 06 Dec 2024

View live Supernus Pharmaceuticals Inc share price in Dollar and Rupees. Guide to invest in Supernus Pharmaceuticals Inc from India. Also see the sentimental analysis on Indian investors investing in Supernus Pharmaceuticals Inc. Get details on the Indian mutual funds that are investing in Supernus Pharmaceuticals Inc. Get Analyst recommendations and forecasts along with all the Supernus Pharmaceuticals Inc's financials.

Supernus Pharmaceuticals Inc share price movements

$36.20
$37.44
$36.97
2.08%
Downside
Day's Volatility :3.31%
Upside
1.26%
$25.53
$39.37
$36.97
30.94%
Downside
52 Weeks Volatility :35.15%
Upside
6.1%

Supernus Pharmaceuticals Inc Returns

Period	Supernus Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	10.25%	-4.7%	0.0%
6 Months	42.08%	0.9%	0.0%
1 Year	36.82%	11.6%	0.0%
3 Years	20.47%	12.9%	-18.1%

Supernus Pharmaceuticals Inc Key Statistics

in dollars & INR

Previous Close	$37.15
Open	$36.83
Today's High	$37.44
Today's Low	$36.2
Market Capitalization	$2.0B
Today's Volume	$347.4K
52 Week High	$39.37
52 Week Low	$25.53
Revenue TTM	$652.0M
EBITDA	$144.0M
Earnings Per Share (EPS)	$1.07
PE Ratio	34.18
Profit Margin	9.16%
Quarterly Earnings Growth YOY	-0.99%
Return On Equity TTM	6.22%

How to invest in Supernus Pharmaceuticals Inc from India?

It is very easy for Indian residents to invest directly in Supernus Pharmaceuticals Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Supernus Pharmaceuticals Inc stock in both rupees (INR) and dollars (USD). Search for Supernus Pharmaceuticals Inc or SUPN on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Supernus Pharmaceuticals Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Supernus Pharmaceuticals Inc shares which would translate to 0.023 fractional shares of Supernus Pharmaceuticals Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Supernus Pharmaceuticals Inc

30%

Period: Sep 6, 2024 to Dec 5, 2024. Change in 30 Days versus previous period

Search volume for Supernus Pharmaceuticals Inc on INDmoney from India has grown in the last 30 days as on Dec 6, 2024. 30% more investors are searching Supernus Pharmaceuticals Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Supernus Pharmaceuticals Inc

BlackRock Inc
18.82%
Vanguard Group Inc
11.10%
Armistice Capital, LLC
9.23%
Dimensional Fund Advisors, Inc.
5.22%
Macquarie Group Ltd
4.77%
State Street Corp
3.91%

Analyst Recommendation on Supernus Pharmaceuticals Inc

Buy

80%Buy

20%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Supernus Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Supernus Pharmaceuticals Inc

What analysts predicted

Upside of 6.17%

Current:

$36.97

Target:

$39.25

Insights on Supernus Pharmaceuticals Inc

Increasing Revenue
Revenue is up for the last 3 quarters, 143.64M → 175.68M (in $), with an average increase of 9.4% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 124.0K → 38.49M (in $), with an average increase of 73.8% per quarter
Vs CTLT
In the last 1 year, Catalent, Inc. has given 57.9% return, outperforming this stock by 23.6%

Supernus Pharmaceuticals Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$408.9M	↑ 35.29%
Net Income	$111.0M	↑ 93.76%
Net Profit Margin	27.14%	↑ 8.19%

	FY19	Y/Y Change
Revenue	$392.8M	↓ 3.95%
Net Income	$113.1M	↑ 1.86%
Net Profit Margin	28.79%	↑ 1.65%

	FY20	Y/Y Change
Revenue	$520.4M	↑ 32.5%
Net Income	$127.0M	↑ 12.29%
Net Profit Margin	24.39%	↓ 4.4%

	FY21	Y/Y Change
Revenue	$579.8M	↑ 11.41%
Net Income	$53.4M	↓ 57.92%
Net Profit Margin	9.21%	↓ 15.18%

	FY22	Y/Y Change
Revenue	$667.2M	↑ 15.09%
Net Income	$60.7M	↑ 13.64%
Net Profit Margin	9.1%	↓ 0.11%

	FY23	Y/Y Change
Revenue	$607.5M	↓ 8.95%
Net Income	$1.3M	↓ 97.83%
Net Profit Margin	0.22%	↓ 8.88%

	Q2 FY23	Q/Q Change
Revenue	$135.6M	↓ 11.84%
Net Income	$-831.0K	↓ 104.9%
Net Profit Margin	-0.61%	↓ 11.63%

	Q3 FY23	Q/Q Change
Revenue	$153.9M	↑ 13.51%
Net Income	$-16.0M	↑ 1822.5%
Net Profit Margin	-10.38%	↓ 9.77%

	Q4 FY23	Q/Q Change
Revenue	$164.3M	↑ 6.78%
Net Income	$1.2M	↓ 107.35%
Net Profit Margin	0.72%	↑ 11.1%

	Q1 FY24	Q/Q Change
Revenue	$143.6M	↓ 12.58%
Net Income	$124.0K	↓ 89.45%
Net Profit Margin	0.09%	↓ 0.63%

	Q2 FY24	Q/Q Change
Revenue	$168.3M	↑ 17.18%
Net Income	$19.9M	↑ 15961.29%
Net Profit Margin	11.83%	↑ 11.74%

	Q3 FY24	Q/Q Change
Revenue	$175.7M	↑ 4.37%
Net Income	$38.5M	↑ 93.3%
Net Profit Margin	21.91%	↑ 10.08%

	FY18	Y/Y Change
Total Assets	$977.8M	↑ 130.36%
Total Liabilities	$524.8M	↑ 234.29%

	FY19	Y/Y Change
Total Assets	$1.2B	↑ 18.66%
Total Liabilities	$564.9M	↑ 7.63%

	FY20	Y/Y Change
Total Assets	$1.5B	↑ 29.63%
Total Liabilities	$759.2M	↑ 34.41%

	FY21	Y/Y Change
Total Assets	$1.7B	↑ 12.3%
Total Liabilities	$873.3M	↑ 15.02%

	FY22	Y/Y Change
Total Assets	$1.7B	↑ 0.79%
Total Liabilities	$816.3M	↓ 6.53%

	FY23	Y/Y Change
Total Assets	$1.3B	↓ 24.95%
Total Liabilities	$356.2M	↓ 56.37%

	Q2 FY23	Q/Q Change
Total Assets	$1.3B	↓ 27.83%
Total Liabilities	$373.2M	↓ 57.58%

	Q3 FY23	Q/Q Change
Total Assets	$1.3B	↓ 0.61%
Total Liabilities	$373.0M	↓ 0.06%

	Q4 FY23	Q/Q Change
Total Assets	$1.4B	↑ 9.63%
Total Liabilities	$487.5M	↑ 30.7%

	Q1 FY24	Q/Q Change
Total Assets	$1.3B	↓ 7.44%
Total Liabilities	$374.9M	↓ 23.09%

	Q2 FY24	Q/Q Change
Total Assets	$1.3B	↑ 0.9%
Total Liabilities	$358.4M	↓ 4.41%

	Q3 FY24	Q/Q Change
Total Assets	$1.3B	↑ 2.04%
Total Liabilities	$335.6M	↓ 6.37%

	FY18	Y/Y Change
Operating Cash Flow	$129.0M	↑ 12.51%
Investing Cash Flow	$-413.5M	↑ 378.48%
Financing Cash Flow	$376.4M	↑ 6526.26%

	FY19	Y/Y Change
Operating Cash Flow	$143.1M	↑ 10.96%
Investing Cash Flow	$-157.9M	↓ 61.81%
Financing Cash Flow	$3.9M	↓ 98.96%

	FY20	Y/Y Change
Operating Cash Flow	$138.4M	↓ 3.3%
Investing Cash Flow	$-34.7M	↓ 78.03%
Financing Cash Flow	$3.6M	↓ 9.39%

	FY21	Y/Y Change
Operating Cash Flow	$127.1M	↓ 8.14%
Investing Cash Flow	$-81.9M	↑ 136.07%
Financing Cash Flow	$-130.4M	↓ 3764.51%

	FY22	Y/Y Change
Operating Cash Flow	$116.8M	↓ 8.1%
Investing Cash Flow	$-216.7M	↑ 164.5%
Financing Cash Flow	$-10.5M	↓ 91.97%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-18.9M	↓ 138.42%
Investing Cash Flow	$60.3M	↓ 74.85%
Financing Cash Flow	$-478.9M	↓ 697.35%

Supernus Pharmaceuticals Inc Technicals Summary

Sell

Neutral

Buy

Supernus Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Supernus Pharmaceuticals Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Supernus Pharmaceuticals Inc	7.4%	42.08%	36.82%	20.47%	64.43%
Neurocrine Biosciences Inc.	3.59%	-6.73%	4.91%	53.06%	10.67%
Haleon Plc Spon Ads	-1.02%	13.5%	17.64%	30.5%	30.5%
Zoetis Inc.	0.88%	-0.06%	-2.76%	-21.66%	45.85%
Viatris Inc.	13.7%	26.07%	35.25%	6.45%	-19.22%
Catalent, Inc.	5.04%	8.94%	64.03%	-50.26%	18.0%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Supernus Pharmaceuticals Inc	34.18	34.18	1.47	2.86	0.06	0.03	NA	18.24
Neurocrine Biosciences Inc.	33.8	33.8	0.3	6.54	0.16	0.12	NA	26.87
Haleon Plc Spon Ads	28.41	28.41	1.72	0.34	0.07	0.04	0.02	1.82
Zoetis Inc.	32.88	32.88	2.44	5.87	0.47	0.15	0.01	11.59
Viatris Inc.	224.4	NA	0.08	2.67	-0.04	0.02	0.04	16.58
Catalent, Inc.	211.02	NA	509.25	0.2	-0.11	0.0	NA	19.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Supernus Pharmaceuticals Inc	Buy	$2.0B	64.43%	34.18	9.16%
Neurocrine Biosciences Inc.	Buy	$12.8B	10.67%	33.8	17.21%
Haleon Plc Spon Ads	Buy	$43.7B	30.5%	28.41	10.75%
Zoetis Inc.	Buy	$79.7B	45.85%	32.88	26.55%
Viatris Inc.	Hold	$15.1B	-19.22%	224.4	-5.87%
Catalent, Inc.	Hold	$11.1B	18.0%	211.02	-9.34%

About Supernus Pharmaceuticals Inc

pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

Organization	Supernus Pharmaceuticals Inc
Employees	652
CEO	Mr. Jack A. Khattar M.B.A.
Industry	Health Technology

Management People of Supernus Pharmaceuticals Inc

Name	Title
Mr. Jack A. Khattar M.B.A.	Founder, President, CEO, Secretary & Director
Mr. Timothy C. Dec	Senior VP & CFO
Dr. Padmanabh P. Bhatt Ph.D.	Chief Scientific Officer & Senior VP of Intellectual Property
Mr. Frank Mottola	Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs
Dr. Jonathan Rubin M.B.A., M.D.	Senior VP of Research & Development and Chief Medical Officer
Mr. Kevin T. Anderson Esq.	Compliance Officer
Dr. Todd Horich M.B.A., Ph.D.	Senior Vice President of Marketing, Commercial Operations & Market Access
Mr. Taylor Raiford	Senior Vice President of Sales
Dr. Bryan A. Roecklein Ph.D.	Senior Vice President of Corporate Development
Mr. Jeff Bozick	Senior Vice President of Supply Chain

Important FAQs about investing in Supernus Pharmaceuticals Inc from India :

What is Supernus Pharmaceuticals Inc share price today?

Supernus Pharmaceuticals Inc (SUPN) share price today is $36.97.

Can Indians buy Supernus Pharmaceuticals Inc shares?

Yes, Indians can invest in the Supernus Pharmaceuticals Inc (SUPN) from India.

With INDmoney, you can buy Supernus Pharmaceuticals Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Supernus Pharmaceuticals Inc at zero transaction cost.

How can I buy Supernus Pharmaceuticals Inc shares from India?

It is very easy to buy Supernus Pharmaceuticals Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Supernus Pharmaceuticals Inc be purchased?

Yes, you can buy fractional shares of Supernus Pharmaceuticals Inc with INDmoney app.

What are the documents required to start investing in Supernus Pharmaceuticals Inc stocks?

To start investing in Supernus Pharmaceuticals Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.